MRE-269-d7
MRE-269-d7 is deuterium labeled MRE-269. MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist[1][2].
Product Specifications
CAS Number
1265295-20-2
Product Name Alternative
ACT-333679-d7
UNSPSC
12352005
Target
Prostaglandin Receptor
Type
Isotope-Labeled Compounds
Related Pathways
GPCR/G Protein
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Purity
99.59
Solubility
10 mM in DMSO|DMSO : 50mg/mL (ultrasonic)
Smiles
OC(COCCCCN(C([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])C1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)N=C1)=O
Molecular Formula
C25H22D7N3O3
Molecular Weight
426.56
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216. |[2]Fuchikami C, et al. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[ (5,6-diphenylpyrazin-2-yl) (isopropyl) amino]butoxy}-N- (methylsulfonyl) acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries. Eur J Pharmacol. 2017 Jan 15;795:75-83.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LC426599 20 µg
Tau (MAPT) (NM_001123067) Human Over-expression Lysate
Sign In for Pricing
View Details 
